提醒成功
微信/QQ登录
搜索
首页
| 产品规范 | |
|---|---|
| Type | In Vivo - Reseach Grade Antibody |
| Host | CHO cells |
| catalog# | B00029 |
| Application | Flow cytometry, animal model study |
| Aliases | programmed cell death protein 1, PD1, CD279, cluster of differentiation 279 |
| Size/Concentration | 1mg/5mg/20mg |
| Isotype | Human IgG1 |
| Storage | Store at 4°C 1 month, store at -20°C to -70°C 12 month. protected from prolonged exposure to light. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Human PD1 |
| Formulation | PBS, pH 7.4 |
Description |
|---|
Spartalizumab Biosimilar uses the same protein sequences as the therapeutic antibody spartalizumab. A humanized monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1, PCD-1), with immune checkpoint inhibitory and antineoplastic activities. Upon administration, spartalizumab binds to PD-1 expressed on activated T cells and blocks the interaction with its ligands, programmed cell death 1 ligand 1 (PD-L1, PD-1L1) and PD-1 ligand 2 (PD-L2, PD-1L2). The inhibition of ligand binding prevents PD-1-mediated signaling and results in both T-cell activation and the induction of T-cell-mediated immune responses against tumor cells. PD-1, an immunoglobulin (Ig) superfamily transmembrane protein and inhibitory receptor, negatively regulates T-cell activation. |
Spartalizumab Biosimilar, Human PD-1 Monoclonal Antibody B00029
规格：
- 1mg
- 5mg
- 20mg
数量：
-
+
说明书：
¥3250
-
分享
-
咨询
-
收藏
联系方式
CONTACT-
联系电话:
0731-88388785 -
公司邮箱:
sales@promab.cn -
公司地址:
湖南省长沙市高新开发区林语路239号顺畅产业园5楼
湖南省长沙市望城区普瑞大道8号出版科技园2号楼
官方微信
产品中心
Product技术服务
service客户留言
message